PORTLAND, Maine, May 08, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, expects to report unaudited financial results for the quarter ended March 31, 2024 after the market closes on Tuesday, May 14, 2024. The Company is planning to host a conference call the next morning, Wednesday, ...

PORTLAND, Maine, May 08, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, expects to report unaudited financial results for the quarter ended March 31, 2024 after the market closes on Tuesday, May 14, 2024. The Company is planning to host a conference call the next morning, Wednesday, ...

PORTLAND, Maine, April 09, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced preliminary, unaudited sales results for the first quarter of 2024, which ended March 31, 2024. Preliminary, Unaudited Total Sales Results: 20242023$ Increase % IncreaseDuring the Three-Month P ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 001-12934 (Commission file number) ImmuCell Corporation (Exact name of registrant as specified in its charter) Delaware 01-0382980 (State of incorporation) (I.R.S. Employer Identification No.) 56 Evergreen Drive, Portland, Maine 04103 (Address of principal executive offices) (Zip Code) (207) 878-2770 ...

财务数据和关键指标变化 - 2023年全年销售额下降6%,但第四季度销售额同比增长30%,主要由于产能提升 [9] - 2023年EBITDA下降290万美元,但第四季度EBITDA同比增加65.7万美元 [9] - 2023年净亏损增加330万美元,主要由于毛利率下降380万美元所致,毛利率下降是由于生产过程中的污染和固定成本摊销 [10] - 公司现金较为紧张,已冻结部分资本支出,并延长了100万美元的信用额度至2025年9月 [10] 各条业务线数据和关键指标变化 - 公司主要产品First Defense的销售和生产情况有所改善,第四季度的产能水平可以达到年化2680万美元的销售额 [9] 公司战略和发展方向及行业竞争 - 公司正在努力解决生产过程中的污染问题,通过改进工艺和控制措施来提高产能和生产效率 [7][8][11] - 公司正在与FDA沟通,希望能够尽快获得Re-Tain产品的上市批准,计划在获批后进行有限推广 [12][13][14][31] 管理层对经营环境和未来前景的评论 - 管理层对2024年前景持乐观态度,认为通过改善生产过程,公司将能够保持较高的产能水平 [9][11] - 管理层表示,尽管现金状况紧张,但有信心通过谨慎管理度过难关 [10][43] 问答环节重要的提问和回答 问题1 **Frank Gasker 提问** - 询问公司生产设施的检查进度 [18][19] - 询问公司的订单积压情况 [20][21][22][23][24][25][26][27] **Michael Brigham 回答** - 生产设施检查工作正在进行,到目前为止进展顺利 [19] - 公司的订单积压情况仍然较高,但第四季度销售有所改善,未来将继续努力消化积压 [21][25][27] 问题2 **Sean Kirkwood 提问** - 询问公司的现金流状况,是否会在今年有所改善 [39][40][41][42][43] - 询问公司Re-Tain业务的亏损情况是否会有所改善 [44][45][46][47][48][49] **Michael Brigham 回答** - 公司现金状况较为紧张,但通过谨慎管理和延长信用额度等措施,有信心度过难关,并期望在2024年实现现金流改善 [43] - Re-Tain业务的亏损预计将有所减少,因为主要的监管成本和投入已经完成 [49]

财务数据和关键指标变化 - 公司在2023年前9个月的EBITDA从2022年同期的正1.3百万美元下降到负2.3百万美元,净亏损从826,000美元增加到4.6百万美元,主要是由于毛利润从6.7百万美元下降到2.6百万美元[8][9] - 公司2023年第三季度的产品销售价值约为5.3百万美元,接近其每季度6百万美元的目标产值的89%[12] 各条业务线数据和关键指标变化 - 公司在2023年前9个月的产成品销售从第一季度的约3.3百万美元增加到第二季度的4百万美元,第三季度进一步增加到5.3百万美元[11] 公司战略和发展方向及行业竞争 - 公司正在努力解决过去12个月面临的生产挑战,包括原料污染事件和设备故障,并已采取措施提高产能和产量[10][11][13] - 公司已经完成了必要的设施改造和新设备安装,将全年产能提高到约30百万美元,目标是每季度生产约6百万美元的产品[11][12] - 公司正在与FDA沟通解决提交新药申请时的沟通误解,希望尽快获得批准,推出一种新的治疗亚临床乳房炎的替代抗生素产品[15][16] 管理层对经营环境和未来前景的评论 - 过去12个月是公司非常具有挑战性的时期,但公司正在努力解决这些问题,对未来保持乐观[17] - 公司鼓励投资者查看最新的财报和公司介绍幻灯片,了解公司的业务策略和目标[18]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 001-12934 (Commission file number) ImmuCell Corporation (Exact name of registrant as specified in its charter) Delaware 01-0382980 (State of Incorporation) (I.R.S. Employer Identification No.) 56 Evergreen Drive, Portland, ME 04103 (Address of principal executive office) (Zip Code) (207) 8 ...

ImmuCell Corporation (NASDAQ:ICCC) Q2 2023 Earnings Conference Call August 11, 2023 9:00 AM ET Company Participants Joe Dorame - Lytham Partners, IR Michael Brigham - President and Chief Executive Officer Conference Call Participants Operator Good day, and welcome to the ImmuCell Corporation Reports Second Quarter Fiscal Year 2023 Financial Results Conference Call. All participants will be in a listen-only mode. [Operator Instructions] After today's presentation, there will be an opportunity to ask question ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 001-12934 (Commission file number) ImmuCell Corporation (Exact name of registrant as specified in its charter) Delaware 01-0382980 (State of Incorporation) (I.R.S. Employer Identification No.) 56 Evergreen Drive, Portland, ME 04103 (Address of principal executive office) (Zip Code) (207) 878-27 ...

ImmuCell Corporation (NASDAQ:ICCC) Q1 2023 Earnings Conference Call May 12, 2023 9:00 AM ET Company Participants Joe Diaz - Managing Partner, Lytham Partners Michael Brigham - President and CEO Operator Good morning, and welcome to ImmuCell Corporation Reports First Quarter 2023 Unaudited Financial Results Conference Call. All participants will be in a listen-only mode. [Operator Instructions] Please note, this event is being recorded. I would now like to turn the conference over to Joe Diaz of Lytham Partn ...